Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11641-11649
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11641
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11641
Management of antiviral drug resistance in chronic hepatitis B
Ki Bae Bang, Hong Joo Kim, Department of Internal Medicine, Sungkyunkwan University Kangbuk Samsung Hospital, Seoul 110-746, South Korea
Author contributions: Bang KB and Kim HJ designed and wrote the review article.
Correspondence to: Hong Joo Kim, MD, PhD, Department of Internal Medicine, Sungkyunkwan University Kangbuk Samsung Hospital, 108, Pyung-Dong, Jongro-Ku, Seoul 110-746, South Korea. hongjoo3.kim@samsung.com
Telephone: +82-2-20018556 Fax: +82-2-20018360
Received: October 21, 2013
Revised: January 10, 2014
Accepted: May 28, 2014
Published online: September 7, 2014
Revised: January 10, 2014
Accepted: May 28, 2014
Published online: September 7, 2014
Core Tip
Core tip: Proliferation of hepatitis B virus (HBV) is the key driver of liver injury and disease progression, and thus sustained HBV suppression is of paramount importance in the management of chronic hepatitis B. Long-term antiviral treatment is usually required to achieve sustained suppression of HBV. However, antiviral drug resistance is a serious problem of long-term antiviral treatment, and this poses a critical challenge. Prevention and proper management of antiviral drug resistance are decisive to long-term success of treatment.